Type 1 Diabetes Market: Market Segments: By Insulin Analog (Rapid-Acting Insulin Analogs, Long-Acting Insulin Analogs and Premix Insulin Analogs); By Drug Class (Insulin and Others); By Insulin Pumps (Insulin Pen, Blood Glucose Meters and Others); By Application (Children and Adults) and Region – Global Analysis of Market Size, Share & Trends for 2014– 2020 and Forecasts to 2030
Type 1 Diabetes Market: Market Segments: By Insulin Analog (Rapid-Acting Insulin Analogs, Long-Acting Insulin Analogs and Premix Insulin Analogs); By Drug Class (Insulin and Others); By Insulin Pumps (Insulin Pen, Blood Glucose Meters and Others); By Application (Children and Adults) and Region – Global Analysis of Market Size, Share & Trends for 2014– 2020 and Forecasts to 2030Product Overview
Diabetes is a metabolic disease in which pancreases is no longer able to secrete adequate insulin inside the pancreas. Diabetes is characterized by high blood glucose or high blood sugar level. Diabetes is primarily of 3 types-type 1, type 2, and diabetes. Type 1 diabetes is a medical condition in which pancreas secrete less or no insulin. It occurs when immune system destroys or attacks the insulin making cells in the pancreas. These cells are known as beta cells.
Market Highlights
Global Type 1 Diabetes Market is expected to project a notable CAGR of XX.X% in 2030.
Global Type 1 Diabetes Market to surpass USD XXXX million by 2030 from USD XXXX million in 2019 at a CAGR of XX.X% in the coming years, i.e., 2020-30. Factors such as sedentary lifestyles, increasing prevalence of chronic diseases ,unhealthy diet routine coupled with growing obesity rates are bolstering the market growth.
Global Type 1 Diabetes Market: Segments
Rapid-Acting Insulin segment to grow with the highest CAGR during 2020-30
Global Type 1 Diabetes market is segmented by Insulin Analog into Rapid-Acting Insulin Analogs, Long-Acting Insulin Analogs and Premix Insulin Analogs. Rapid-Acting Insulin, segment held the largest market share of XX.X% in the year 2019 as they act very quickly to reduce the rise in blood sugar level which follows eating. Rapid-Acting Insulin is usually taken just before or with the meal. It can either be delivered or injected through an insulin pump.
Market Dynamics
Drivers
Technological advances in insulin delivery
Advent of several new class of diabetics drugs and advancements in insulin delivery are the key factors propelling the market growth. The growing demand for minimally invasive and non-invasive insulin delivery is expected to spur the market growth in the near future. The introduction of early insulin pumps and blood glucose meters, the development of new technologies and integration of consumer electronics and cloud-based data systems is likely to provide a strong impetus to the market growth. Other factors that are driving the market growth includes approval of insulin smart pens that records the timing and amount of insulin doses, with information exchanged with mobile apps to monitor patterns and make recommendations for dosing, developments in CGM and insulin pump technology, and the incorporation of CGM and insulin pumps into hybrid closed-loop systems that can change the delivery of insulin on the basis of live glucose measurements.
Restraint
High cost of treatment
Treatment therapies and diagnosis cost associated with diabetes is considerably high which can hinder the growth of type 1 diabetes market globally. Besides, unfavorable reimbursement policies is anticipated to inhibit the growth of market in the coming years.
Global Type 1 Diabetes Market: Key Players
Abbott Laboratories
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Bayer AG
Eli Lilly and Company
GlaxoSmithKline
Johnson & Johnson Ltd
Merck & C0.
Pfizer Inc.
Takeda Pharmaceutical
AstraZeneca PLC.
XOMA Corp
Other Prominent Players
Global Type 1 Diabetes Market: Regions
Global Type 1 Diabetes Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific and Middle East and Africa. Global Type 1 Diabetes Market in North America held the largest market share of XX.X% in the year 2019. North America will continue to dominate the global Type 1 Diabetes market owing to rising healthcare expenditure, growing geriatric population and changing lifestyle of people. In addition, several diabetes control and awareness initiatives organized by government in the region is anticipated to further bolster the market growth. High adoption of technological advancements in the region is projected to support the market growth.
Diabetes is a metabolic disease in which pancreases is no longer able to secrete adequate insulin inside the pancreas. Diabetes is characterized by high blood glucose or high blood sugar level. Diabetes is primarily of 3 types-type 1, type 2, and diabetes. Type 1 diabetes is a medical condition in which pancreas secrete less or no insulin. It occurs when immune system destroys or attacks the insulin making cells in the pancreas. These cells are known as beta cells.
Market Highlights
Global Type 1 Diabetes Market is expected to project a notable CAGR of XX.X% in 2030.
Global Type 1 Diabetes Market to surpass USD XXXX million by 2030 from USD XXXX million in 2019 at a CAGR of XX.X% in the coming years, i.e., 2020-30. Factors such as sedentary lifestyles, increasing prevalence of chronic diseases ,unhealthy diet routine coupled with growing obesity rates are bolstering the market growth.
Global Type 1 Diabetes Market: Segments
Rapid-Acting Insulin segment to grow with the highest CAGR during 2020-30
Global Type 1 Diabetes market is segmented by Insulin Analog into Rapid-Acting Insulin Analogs, Long-Acting Insulin Analogs and Premix Insulin Analogs. Rapid-Acting Insulin, segment held the largest market share of XX.X% in the year 2019 as they act very quickly to reduce the rise in blood sugar level which follows eating. Rapid-Acting Insulin is usually taken just before or with the meal. It can either be delivered or injected through an insulin pump.
Market Dynamics
Drivers
Technological advances in insulin delivery
Advent of several new class of diabetics drugs and advancements in insulin delivery are the key factors propelling the market growth. The growing demand for minimally invasive and non-invasive insulin delivery is expected to spur the market growth in the near future. The introduction of early insulin pumps and blood glucose meters, the development of new technologies and integration of consumer electronics and cloud-based data systems is likely to provide a strong impetus to the market growth. Other factors that are driving the market growth includes approval of insulin smart pens that records the timing and amount of insulin doses, with information exchanged with mobile apps to monitor patterns and make recommendations for dosing, developments in CGM and insulin pump technology, and the incorporation of CGM and insulin pumps into hybrid closed-loop systems that can change the delivery of insulin on the basis of live glucose measurements.
Restraint
High cost of treatment
Treatment therapies and diagnosis cost associated with diabetes is considerably high which can hinder the growth of type 1 diabetes market globally. Besides, unfavorable reimbursement policies is anticipated to inhibit the growth of market in the coming years.
Global Type 1 Diabetes Market: Key Players
Abbott Laboratories
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Bayer AG
Eli Lilly and Company
GlaxoSmithKline
Johnson & Johnson Ltd
Merck & C0.
Pfizer Inc.
Takeda Pharmaceutical
AstraZeneca PLC.
XOMA Corp
Other Prominent Players
Global Type 1 Diabetes Market: Regions
Global Type 1 Diabetes Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific and Middle East and Africa. Global Type 1 Diabetes Market in North America held the largest market share of XX.X% in the year 2019. North America will continue to dominate the global Type 1 Diabetes market owing to rising healthcare expenditure, growing geriatric population and changing lifestyle of people. In addition, several diabetes control and awareness initiatives organized by government in the region is anticipated to further bolster the market growth. High adoption of technological advancements in the region is projected to support the market growth.
1. EXECUTIVE SUMMARY
2. GLOBAL TYPE 1 DIABETES MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL TYPE 1 DIABETES MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL TYPE 1 DIABETES MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL TYPE 1 DIABETES MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Insulin Analog: Market Share (2020-2030F)
12.2.1. Rapid-Acting Insulin Analogs, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Long-Acting Insulin Analogs, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Premix Insulin Analogs, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Drug Class: Market Share (2020-2030F)
12.3.1. Insulin, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Insulin Pumps: Market Share (2020-2030F)
12.4.1. Insulin Pen, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Blood Glucose Meters, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
12.5. By Application: Market Share (2020-2030F)
12.5.1. Children, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.2. Adults, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. COMPANY PROFILE
14. ABBOTT LABORATORIES
14.1. Company Overview
14.2. Company Total Revenue (Financials)
14.3. Market Potential
14.4. Global Presence
14.5. Key Performance Indicators
14.6. SWOT Analysis
14.7. Product Launch
15. BAYER AG
16. ELI LILLY AND COMPANY
17. GLAXOSMITHKLINE
18. JOHNSON & JOHNSON LTD.
19. MERCK & C0.
20. PFIZER INC.
21. TAKEDA PHARMACEUTICAL
22. ASTRAZENECA PLC.
23. XOMA CORP
24. OTHER PROMINENT PLAYERS
Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. GLOBAL TYPE 1 DIABETES MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL TYPE 1 DIABETES MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL TYPE 1 DIABETES MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL TYPE 1 DIABETES MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Insulin Analog: Market Share (2020-2030F)
12.2.1. Rapid-Acting Insulin Analogs, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Long-Acting Insulin Analogs, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Premix Insulin Analogs, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Drug Class: Market Share (2020-2030F)
12.3.1. Insulin, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Insulin Pumps: Market Share (2020-2030F)
12.4.1. Insulin Pen, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Blood Glucose Meters, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
12.5. By Application: Market Share (2020-2030F)
12.5.1. Children, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5.2. Adults, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. COMPANY PROFILE
14. ABBOTT LABORATORIES
14.1. Company Overview
14.2. Company Total Revenue (Financials)
14.3. Market Potential
14.4. Global Presence
14.5. Key Performance Indicators
14.6. SWOT Analysis
14.7. Product Launch
15. BAYER AG
16. ELI LILLY AND COMPANY
17. GLAXOSMITHKLINE
18. JOHNSON & JOHNSON LTD.
19. MERCK & C0.
20. PFIZER INC.
21. TAKEDA PHARMACEUTICAL
22. ASTRAZENECA PLC.
23. XOMA CORP
24. OTHER PROMINENT PLAYERS
Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
